Zimmer Biomet Shares Face Selling Pressure Amid Divergent Investor Moves

Shares of medical device manufacturer Zimmer Biomet are experiencing notable downward pressure in today’s trading session. This movement follows disclosures of significant position reductions by major institutional holders during the second quarter, coupled with a reiterated bearish stance from Goldman Sachs analysts.

Recent regulatory filings reveal a wave of selling by prominent investment firms in Q2 2025. European asset manager Amundi slashed its stake by 38.7%, selling 401,103 shares, which reduces its holding to approximately 0.32% of the company. Concurrently, hedge fund Marshall Wace LLP cut its position by 28.3%, involving 98,367 shares.

This selling activity aligns with continued skepticism from Wall Street research. An analyst at Goldman Sachs has reaffirmed a ‘Sell’ Read more...